Our Mission
The Oxford Vaccine Group has been at the forefront of vaccine development for 30 years, helping to fight diseases of major global importance through research and education around the world.
What's Happening?
30 Years of OVG
1994 - 2024
Join our celebrations and learn about 30 years of ground-breaking research at OVG
Study Spotlight
| eclipse👤 18-49 or 60-80 years old 📅 Up to 5 or 9 visits over 31 days 💉 Group A: 1 vaccination and 1 inoculation. Group B: 1 vaccination 🧬 A study to understand how the body reacts to a combination of the flu virus and pneumococcal bacteria. 🪙 Up to £700 or £1060 reimbursement (dependent on group) |
Be a Vaccine Hero
Take part in a study
Could you be a Vaccine Hero by taking part in one of our clinical trials? Find out about the trials and studies currently looking for volunteers, as well as what it is like taking part from previous participants
Study - LEGACY02
A study examining lymph node cells to assess how age affects immune responses to a new vaccine.
Study - STELLAR
This study will compare the protective response to infections (also called an immune response) in the nose to the protective response in the blood following vaccination with a safe and effective nasal influenza vaccine
Study - MAGIC-01
A study of a new vaccine against Marburg Virus
Research at OVG
Education, Learning and Public Involvement
Latest Publications
⠀⠀⠀⠀⠀
-
Five-Year Vaccine Protection Following a Single Dose of Vi-Tetanus Toxoid Conjugate Vaccine in Bangladeshi Children: A Cluster Randomised Trial
Journal article
Qadri F. et al, (2024)
-
Essential role of proline synthesis and the one-carbon metabolism pathways for systemic virulence of Streptococcus pneumoniae.
Journal article
Ramos-Sevillano E. et al, (2024), mBio, 15
-
Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth
Journal article
Pollock K. et al, (2024), EBioMedicine
-
Navigating vaccine procurement and financing challenges in Cameroon: Insights and recommendations from a mixed-methods study (2015-2020).
Journal article
Saidu Y. et al, (2024), Public Health, 237, 261 - 269
Working Together
National Immunisation Schedule Evaluation Consortium II
OVG is proud to lead NISEC II, a collaboration between a network of Academic Clinical Research groups and the UK Health Security Agency.
Immune Memory and Mechanisms of Protection from Vaccines
Oxford is proud to host the IMMPROVE consortium of universities, government, industry and others.
